Your browser doesn't support javascript.
loading
Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions.
Mattoo, Hamid; Pillai, Shiv.
Afiliação
  • Mattoo H; Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, MA, USA.
  • Pillai S; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. pillai@helix.mgh.harvard.edu.
Cell Mol Life Sci ; 78(14): 5527-5542, 2021 Jul.
Article em En | MEDLINE | ID: mdl-34145462
ABSTRACT
Fibrotic diseases take a very heavy toll in terms of morbidity and mortality equal to or even greater than that caused by metastatic cancer. In this review, we examine the pathogenesis of fibrotic diseases, mainly addressing triggers for induction, processes that lead to progression, therapies and therapeutic trials. For the most part, we have focused on two fibrotic diseases with lung involvement, idiopathic pulmonary fibrosis, in which the contribution of inflammatory mechanisms may be secondary to non-immune triggers, and systemic sclerosis in which the contribution of adaptive immunity may be predominant.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Fibrose Pulmonar Idiopática Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Cell Mol Life Sci Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Fibrose Pulmonar Idiopática Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Cell Mol Life Sci Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos